Information on the execution of tests in the IQE environment
Note: This information is addressed to the End-Users who are to perform tests in the NMVS-IQE (prior to obtaining access to NMVS/after the implementation of a new major version of the NMVS)

IQE Testing EN

Instructiuni-Cod_Datamatrix_.docx

Obtaining and Maintaining the Access to the NMVS

The End-Users’ registration process to the National Medicines Verification System (NMVS) includes, as a mandatory preliminary step for the access to the production environment (PROD) of NMVS, the execution of tests by the End-Users in the test environment (IQE).

OSMR provides the necessary information for the End-Users to perform the test scenarios, in order to complete the testing process in the NMVS-IQE environment, information available on this page and detailed in the End-Users’ Instructions’ Manual

Following the verifications carried out by OSMR regarding the accuracy of the tests executed by the End-Users as well as the LUF (End-Users’ Location) accounts created in the test environment, we would like to remind you that all End-Users have the obligation to create at least one LUF exclusively in the test environment (IQE) and initiate a number of 8 test scenarios.

OSMR recommends that before upgrading to a new major version of NMVS (e.g.: 2.0; 3.0; 4.0), the End-Users perform the tests in the test environment (IQE), using the test scenarios which can be found in form OSMR-PSO-0010/F1 – Testing Report (IQE) for the NMVS End-Users.

In order to correct the data/accounts, OSMR will continue the verification and notification of End-Users, for whom the tests in the IQE environment and/or LUF accounts have not been executed according to the Instructions’ Manual.

We remind you that obtaining and maintaining access to NMVS’s production environment is conditioned by the accurate creation of the LUF and the documented existence of test transactions by uploading the Test Report to the SIMI account (Registering and Incident Management System).

Clarification of API tests in the NMVS IQE environment

OSMR aims to proactively offer End-Users the necessary clarifications to carry out the mandatory testing process in the National Medicines Verification System (NMVS) test environment (IQE).

The Local Application (Application Programming Interface – API) – represents any software application used by the End-Users (pharmacies, wholesalers, hospitals) to connect to the National Medicines Verification System (NMVS) in order to carry out activities related to the serialization process (e.g.: decommissioning, verification), prior to medicines being released to the patients.

API Tests are addressed exclusively to the Local Application.
We would like to mention here that there are End-Users with restricted access – according to the legal requirements, which do not use the local application (API), thus the only tests that can be done are those carried out via the WEB interface.

If you do not have the technical knowledge required in order to perform the API tests, please contact the software supplier you collaborate with to connect your application to the NMVS.

Therefore, it is the responsibility of both the End-Users and their software providers to ensure the NMVS connection solution is properly qualified and that all due diligence is performed, by carrying out the mandatory tests in the IQE environment.

On 19.07.2019, on the NMVS integrated quality environment (IQE) a new major version of the NMVS application was rolled out.
Therefore, please be informed that starting with 30.07.2019 OSMR has created the corresponding ADMIN accounts for each End-User.

OSMR recommends that before upgrading to a new major version of NMVS (e.g.: 2.0; 3.0; 4.0), the End-Users perform the tests in the test environment (IQE), using the test scenarios which can be found in form OSMR-PSO-0010/F1 – Testing Report (IQE) for the NMVS End-Users.

Please, after completing the tests, upload the report in crm simi, under the document type “iqe report”.
The lack of the Testing Report in CRM SIMI can lead to loss of access rights to the NMVS.

Testing Report